about
T(H)17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26Purpura of the face and neck: an atypical clinical presentation revealing a hepatosplenic T cell lymphoma.Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus.Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alphaAnimal models of psoriasis and psoriatic arthritis: an update.Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cellsCutting edge: A critical functional role for IL-23 in psoriasis.Melanoma and innate immunity--aActive inflammation or just erroneous attraction? Melanoma as the source of leukocyte-attracting chemokines.Trauma as triggering factor for development of melanocytic nevi.The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologists.Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris.Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry.Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.Xenotransplantation Model of Psoriasis.PASS Syndrome: An IL-1-Driven Autoinflammatory Disease.[Rosacea: what's new?].Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: A dangerous liaison.The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis.Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA.Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease.Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.Diversification of human plasmacytoid predendritic cells in response to a single stimulus.Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris.Psoriasis: from Pathogenesis to Targeted Therapies.TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis.Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis.The pathogenic role of tissue-resident immune cells in psoriasis.[Management of ulcerative colitis in 2017].Anti-TNF therapy in the treatment of psoriasis in a patient with acute-on-chronic pancreatitis.Targeting CD8+ T cells prevents psoriasis developmentErratum: Corrigendum: The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis[Development of skin diseases in intravenous drug dependent patients treated with heroin substitution]CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotypePyoderma gangrenosumType I IFNs at the interface between cutaneous immunity and epidermal remodeling[Psoriasis: advances and challenges in 2015]Human "TH9" cells are a subpopulation of PPAR-γ+ TH2 cells
P50
Q28264988-3192FC8C-3F22-4D7B-886C-973C64679A18Q33414463-8043990B-ECA9-4DE2-AEB8-10D6C29C69BCQ36102468-7079177A-7CB3-4BF8-9EEA-0D18CA0779AAQ36402885-E6905FA1-10F0-44DA-A55A-F79CDD4B69B8Q36403890-EBECAE6B-4F7D-43C8-8CBC-2F2AC578D73AQ36594219-5021E77C-3351-4ED3-9FD3-C9E1CEE4D6BBQ36839509-229C1C30-0AC7-423A-BA5F-8C1EC899993AQ37180687-C4A01E70-E76C-453D-9440-7FAD386DD3F3Q37336165-6B5CA8C7-A807-4F1B-9F4F-6EB1B18CEE6AQ37737926-4BA8C5DB-0D2C-4AC0-82E0-856B9FD15BC6Q38312217-AC6559EF-6070-48BB-9B0E-9A2631093869Q38870525-5FA741F3-92E4-47E6-BBAC-B3395E91E132Q39012185-800205A1-24FA-4C0E-B169-492246B77181Q39026710-D3C3B239-D5C1-4CE0-897C-1900B2B0CE39Q39072299-F2D42D44-2E1D-4450-AAC1-BE095298ACC2Q40116484-B53069F3-BF5E-44B3-91E5-4057C2AF03C4Q40757509-52134F6B-6034-4925-8181-1F38FC9C0D1CQ41218764-564BFB96-3D20-4CDE-9D60-140093481FFAQ41620801-33373276-65B5-489B-AC70-9B963867BCCEQ41693956-8940B20B-5F6D-4B26-BD40-A190D6BB7561Q42482098-4EAE38EF-214E-4BB9-A63B-231998865450Q44285977-5256B372-BA70-4067-8FF0-90BF7F9DAD8AQ45196039-24400C87-2789-4596-9D11-6796F0214D6BQ46435959-B3659F0B-7A98-490B-9DD9-B07C493DB9CEQ47331935-1BB74B79-3288-41CE-B988-2A15E37B4248Q47577626-8BD40B97-14AC-45BE-8D33-F919478CAFD3Q47724381-8183D233-0ACA-4ED7-B3E4-804779D34803Q48319094-9C28E640-2883-4035-BE57-8A81CC67EDD4Q51974034-ED5B7092-5799-4A55-8D97-0F480CF054E8Q53580140-7B6F1DB6-11B4-47BD-A9F0-022827B051E7Q53739734-EE96C88A-D0A1-4D92-AB67-0A96762E43B5Q54658776-72480AE2-CEB5-4103-BD6F-125BD7C52E60Q58235903-D48BDB13-7A19-4A4B-822C-A413E2A709BFQ58434806-724CFA6C-ACFD-4B1A-9DEF-770BE400E0C6Q73283951-3F6E3F3C-E1A8-4804-AE98-BF3CD528AB6CQ81192927-D8E87F9B-9705-4A54-904B-B81BF69A096FQ82059431-EA1B9FDC-588B-4F7C-AF83-02622D294C83Q84370896-1CFA0E4F-54D9-41F6-84B0-76AEDBD2FEF8Q85233296-93AD0422-D1A1-45A1-80BC-9EB699A744A2Q91116398-72A69CDC-FC50-4A68-AD56-BB41EC18AAC5
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Curdin Conrad
@ast
Curdin Conrad
@en
Curdin Conrad
@es
Curdin Conrad
@nl
type
label
Curdin Conrad
@ast
Curdin Conrad
@en
Curdin Conrad
@es
Curdin Conrad
@nl
prefLabel
Curdin Conrad
@ast
Curdin Conrad
@en
Curdin Conrad
@es
Curdin Conrad
@nl
P106
P1153
8058293100
P31
P496
0000-0002-2547-3440